Cargando…
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dul...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055818/ https://www.ncbi.nlm.nih.gov/pubmed/29603872 http://dx.doi.org/10.1111/dom.13313 |
_version_ | 1783341255050133504 |
---|---|
author | Mathieu, Chantal Del Prato, Stefano Botros, Fady T. Thieu, Vivian T. Pavo, Imre Jia, Nan Haupt, Axel Karanikas, Chrisanthi A. García‐Pérez, Luis‐Emilio |
author_facet | Mathieu, Chantal Del Prato, Stefano Botros, Fady T. Thieu, Vivian T. Pavo, Imre Jia, Nan Haupt, Axel Karanikas, Chrisanthi A. García‐Pérez, Luis‐Emilio |
author_sort | Mathieu, Chantal |
collection | PubMed |
description | Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide‐treated patients from AWARD‐1, AWARD‐3 and AWARD‐6 clinical studies were categorised based on their homeostatic model assessment of beta‐cell function (HOMA2‐%B) tertiles. Changes in glycaemic measures in response to treatment with once‐weekly dulaglutide were evaluated in each HOMA2‐%B tertile. Patients with low HOMA2‐%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P < .001, all) (mean low, middle and high tertiles with dulaglutide 1.5 mg: HOMAB‐2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26 weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5 mg (mean; −1.55% vs. −0.98% [−16.94 vs. −10.71 mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; −1.00 vs. −1.18% [−10.93 vs. −12.90 mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C‐peptide were observed in the low tertile. Similar increases in HOMA2‐%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta‐cell function. |
format | Online Article Text |
id | pubmed-6055818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60558182018-07-30 Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme Mathieu, Chantal Del Prato, Stefano Botros, Fady T. Thieu, Vivian T. Pavo, Imre Jia, Nan Haupt, Axel Karanikas, Chrisanthi A. García‐Pérez, Luis‐Emilio Diabetes Obes Metab Brief Reports Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide‐treated patients from AWARD‐1, AWARD‐3 and AWARD‐6 clinical studies were categorised based on their homeostatic model assessment of beta‐cell function (HOMA2‐%B) tertiles. Changes in glycaemic measures in response to treatment with once‐weekly dulaglutide were evaluated in each HOMA2‐%B tertile. Patients with low HOMA2‐%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P < .001, all) (mean low, middle and high tertiles with dulaglutide 1.5 mg: HOMAB‐2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26 weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5 mg (mean; −1.55% vs. −0.98% [−16.94 vs. −10.71 mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; −1.00 vs. −1.18% [−10.93 vs. −12.90 mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C‐peptide were observed in the low tertile. Similar increases in HOMA2‐%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta‐cell function. Blackwell Publishing Ltd 2018-05-02 2018-08 /pmc/articles/PMC6055818/ /pubmed/29603872 http://dx.doi.org/10.1111/dom.13313 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Reports Mathieu, Chantal Del Prato, Stefano Botros, Fady T. Thieu, Vivian T. Pavo, Imre Jia, Nan Haupt, Axel Karanikas, Chrisanthi A. García‐Pérez, Luis‐Emilio Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title | Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title_full | Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title_fullStr | Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title_full_unstemmed | Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title_short | Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme |
title_sort | effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the award programme |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055818/ https://www.ncbi.nlm.nih.gov/pubmed/29603872 http://dx.doi.org/10.1111/dom.13313 |
work_keys_str_mv | AT mathieuchantal effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT delpratostefano effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT botrosfadyt effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT thieuviviant effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT pavoimre effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT jianan effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT hauptaxel effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT karanikaschrisanthia effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme AT garciaperezluisemilio effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme |